Daniel Passeri - Mar 31, 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Mar 31, 2022
Transactions value $
-$156,755
Form type
4
Date filed
4/4/2022, 05:29 PM
Previous filing
Mar 29, 2022
Next filing
Feb 21, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Options Exercise +75K +75.99% 174K Mar 31, 2022 Direct F1
transaction CUE Common Stock Tax liability -$157K -32.1K -18.49% $4.88 142K Mar 31, 2022 Direct
transaction CUE Common Stock Gift $0 -10K -7.06% $0.00 132K Mar 31, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Restricted Stock Units Options Exercise $0 -75K -100% $0.00* 0 Mar 31, 2022 Common Stock 75K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Each restricted stock unit award represents a contingent right to receive one share of common stock.
F3 One half of the Restricted Stock Units vested on September 30, 2021 and the balance vested on March 31, 2022.